Since their first experimental application in MM in 1984, where MMC and CP prevailed in a mice model and were successfully administered in a clinical trial [36], both agents have maintained their significance in the treatment of peritoneal MM [37]. The gene discussed is CP; the disease is Miyoshi myopathy.